JP2014505049A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505049A5
JP2014505049A5 JP2013547780A JP2013547780A JP2014505049A5 JP 2014505049 A5 JP2014505049 A5 JP 2014505049A5 JP 2013547780 A JP2013547780 A JP 2013547780A JP 2013547780 A JP2013547780 A JP 2013547780A JP 2014505049 A5 JP2014505049 A5 JP 2014505049A5
Authority
JP
Japan
Prior art keywords
ccr2
pharmaceutically acceptable
acceptable salt
angiotensin receptor
pathway inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013547780A
Other languages
English (en)
Japanese (ja)
Other versions
JP6087836B2 (ja
JP2014505049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2012/000014 external-priority patent/WO2012094703A1/en
Publication of JP2014505049A publication Critical patent/JP2014505049A/ja
Publication of JP2014505049A5 publication Critical patent/JP2014505049A5/ja
Application granted granted Critical
Publication of JP6087836B2 publication Critical patent/JP6087836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013547780A 2011-01-11 2012-01-11 併用療法 Active JP6087836B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2011900060A AU2011900060A0 (en) 2011-01-11 Combination Therapy
AU2011900060 2011-01-11
AU2011904279 2011-10-17
AU2011904279A AU2011904279A0 (en) 2011-10-17 Combination Therapy
PCT/AU2012/000014 WO2012094703A1 (en) 2011-01-11 2012-01-11 Combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016247754A Division JP2017078085A (ja) 2011-01-11 2016-12-21 併用療法

Publications (3)

Publication Number Publication Date
JP2014505049A JP2014505049A (ja) 2014-02-27
JP2014505049A5 true JP2014505049A5 (enExample) 2015-02-19
JP6087836B2 JP6087836B2 (ja) 2017-03-01

Family

ID=46506697

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013547780A Active JP6087836B2 (ja) 2011-01-11 2012-01-11 併用療法
JP2016247754A Pending JP2017078085A (ja) 2011-01-11 2016-12-21 併用療法
JP2018101282A Pending JP2018127498A (ja) 2011-01-11 2018-05-28 併用療法
JP2020084905A Pending JP2020122015A (ja) 2011-01-11 2020-05-14 併用療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016247754A Pending JP2017078085A (ja) 2011-01-11 2016-12-21 併用療法
JP2018101282A Pending JP2018127498A (ja) 2011-01-11 2018-05-28 併用療法
JP2020084905A Pending JP2020122015A (ja) 2011-01-11 2020-05-14 併用療法

Country Status (9)

Country Link
US (6) US9314450B2 (enExample)
EP (3) EP4215194A1 (enExample)
JP (4) JP6087836B2 (enExample)
CN (2) CN107899012A (enExample)
AU (1) AU2012206945B2 (enExample)
CA (1) CA2821985C (enExample)
IL (1) IL227414A (enExample)
WO (1) WO2012094703A1 (enExample)
ZA (1) ZA201305897B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2793657A1 (en) 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
JP2014520811A (ja) 2011-06-29 2014-08-25 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 統合失調症の易罹病性及び認知機能障害と関連付けられるニューロン結合の阻害剤
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014075096A1 (en) * 2012-11-09 2014-05-15 The Trustees Of Columbia University In The City Of New York Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2
US9579309B2 (en) 2013-02-28 2017-02-28 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for posterior ocular disease containing tetrahydropyranylaminocyclopentylcarbonyltetrahydropyridopyridine derivative as effective ingredient
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
EP2961483A4 (en) * 2013-03-01 2017-03-08 The Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
CN103193771B (zh) * 2013-03-29 2015-08-05 中国人民解放军军事医学科学院生物工程研究所 链状酰胺类ccr5受体抑制剂的药物新用途
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
JP2016029037A (ja) * 2014-07-17 2016-03-03 参天製薬株式会社 後眼部疾患の予防または治療剤
CN106999593A (zh) * 2014-09-12 2017-08-01 妥必徕疗治公司 用于纤维化治疗的赛尼克韦罗组合疗法
RU2018113437A (ru) * 2015-09-16 2019-10-17 Тобира Терапьютикс, Инк. Комбинированная терапия с использованием ценикривирока для лечения фиброза
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
IL294410B2 (en) * 2016-11-23 2024-02-01 Chemocentryx Inc Method of treating focal segmental glomerulosclerosis
CN111417389A (zh) 2017-10-11 2020-07-14 坎莫森特里克斯公司 Ccr2拮抗剂对局灶性节段性肾小球硬化症的治疗
CN108218789A (zh) * 2018-03-12 2018-06-29 钦州学院 碳13氘代甲基替米沙坦及其制备方法和用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
MX2021012163A (es) * 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
KR20220070435A (ko) * 2019-09-26 2022-05-31 디메릭스 바이오사이언스 피티와이 엘티디 질환의 치료를 위한 방법 및 조성물
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA
GB202006079D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
WO2021222972A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
WO2022198264A1 (en) * 2021-03-23 2022-09-29 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd
TW202444344A (zh) * 2023-05-12 2024-11-16 澳大利亞商迪美力士生物科技有限公司 用於腎病之治療調配物
CN117054652B (zh) * 2023-08-04 2024-05-17 南京医科大学 一种用于辅助检测心肌肥厚的生物标志物及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH059116A (ja) 1991-07-01 1993-01-19 Sanwa Kagaku Kenkyusho Co Ltd ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤
ES2175098T3 (es) * 1995-06-07 2002-11-16 Searle & Co Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo.
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
JP2002528721A (ja) 1998-10-23 2002-09-03 グラクソ グループ リミテッド 核内受容体のリガンド用のアッセイ
ES2293973T3 (es) * 2000-02-03 2008-04-01 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
WO2003014110A1 (en) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Benzazepine derivative, process for producing the same, and use
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
JP2004093527A (ja) 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
EP1481996A1 (en) 2003-05-30 2004-12-01 KRATON Polymers Research B.V. Process for making a coupled block copolymer composition
JP4734498B2 (ja) 2003-07-09 2011-07-27 ライフ テクノロジーズ コーポレイション タンパク質−タンパク質相互作用を解析する方法
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
CA2546764A1 (en) 2003-11-19 2005-06-02 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
EP1787647B1 (en) * 2004-09-06 2012-06-20 Kowa Company, Ltd. Remedy for glomerular diseases
PE20060594A1 (es) * 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
GB0612630D0 (en) 2006-06-26 2006-08-02 Novartis Ag Organic compounds
CA2669088C (en) 2006-11-10 2016-04-05 Dimerix Bioscience Pty Ltd Detection system and uses therefor
EP2092360B1 (en) 2006-11-10 2017-07-12 Koninklijke Philips N.V. Preventing quench in a magnetic resonance examination system
CN101534824A (zh) * 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
WO2008113095A1 (en) * 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
JP2010540527A (ja) * 2007-09-25 2010-12-24 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのオクタヒドロペンタレン化合物
WO2009073683A2 (en) * 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
US20110092463A1 (en) 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
KR20110103987A (ko) 2008-12-01 2011-09-21 인베이스크 테라퓨틱, 인크. 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도
US8537791B2 (en) 2009-01-20 2013-09-17 Lg Electronics Inc. Method and apparatus for channel access in contention-based communication system and station
CA2756743A1 (en) 2009-03-27 2010-09-30 Dimerix Bioscience Pty Ltd. Novel receptor hetero-dimers/-oligomers

Similar Documents

Publication Publication Date Title
JP2014505049A5 (enExample)
Michel et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
JP2018507244A5 (enExample)
JP6087836B2 (ja) 併用療法
DK3027183T3 (en) SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT
CN1312715A (zh) 缬沙坦和钙通道阻断剂的抗超敏组合
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
CO6180425A2 (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos
JP2020536919A5 (enExample)
JP2016512817A5 (enExample)
JP2017520562A5 (enExample)
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
Riva et al. Which is the optimal antihypertensive combination in different diseases, a renin-angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
Lam Azilsartan: a newly approved angiotensin II receptor blocker
CN1249682A (zh) 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂
CA2798573A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
Stone et al. ST91 [2-(2, 6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional α-2A-or α-2C-adrenergic receptors
JP2018521077A5 (enExample)
RU2016103099A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - i
Parvanova et al. Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade
Hou et al. Optimal dose of angiotensin‐converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
Vaněčková et al. Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade
JP2016505628A5 (enExample)
Hashemzadeh et al. A novel design of combining the angiotensin converting enzyme (ACE) inhibitor captopril with the angiotensin receptor blocker (ARB) losartan using homo coupling via PEG diacid linker
Tocci et al. Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy